At ESMO GI 2026, experts presented the EBAI framework classifying AI-based biomarkers into three validation tiers. Clinical data showed AI detecting MSI with 96-98% sensitivity and MRI-guided brachytherapy improving recurrence-free survival.
Whole genome sequencing, comprehensive genomic profiling, and spatial multiomics are transforming precision medicine from research tools to clinical applications in oncology, rare diseases, and neonatal care, enabling faster diagnoses and personalized treatments.
Lynch syndrome patients gain access to prevention vaccines in clinical trials, while immunotherapy advances depend on universal tumor testing for microsatellite instability. Cancer vaccines are moving from research to clinical reality.
